Last reviewed · How we verify
Imovax® Rabies: inactivated rabies vaccine
Imovax® Rabies: inactivated rabies vaccine is a Inactivated vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development for Prevention of rabies. Also known as: Imovax® Rabies.
Stimulates the production of antibodies against rabies virus
Stimulates the production of antibodies against rabies virus Used for Prevention of rabies.
At a glance
| Generic name | Imovax® Rabies: inactivated rabies vaccine |
|---|---|
| Also known as | Imovax® Rabies |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
This inactivated vaccine works by introducing a harmless piece of the rabies virus to the body, which triggers an immune response and the production of antibodies that can fight the virus.
Approved indications
- Prevention of rabies
Common side effects
- Pain, redness, swelling at injection site
- Fatigue
- Headache
Key clinical trials
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults (PHASE3)
- A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults (PHASE1)
- Responses to Rabies Vaccine in Adults With or Without Antibiotics (PHASE4)
- Efficacy and Safety of Dengue Vaccine in Healthy Children (PHASE2)
- Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use (PHASE2)
- Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imovax® Rabies: inactivated rabies vaccine CI brief — competitive landscape report
- Imovax® Rabies: inactivated rabies vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Imovax® Rabies: inactivated rabies vaccine
What is Imovax® Rabies: inactivated rabies vaccine?
How does Imovax® Rabies: inactivated rabies vaccine work?
What is Imovax® Rabies: inactivated rabies vaccine used for?
Who makes Imovax® Rabies: inactivated rabies vaccine?
Is Imovax® Rabies: inactivated rabies vaccine also known as anything else?
What drug class is Imovax® Rabies: inactivated rabies vaccine in?
What development phase is Imovax® Rabies: inactivated rabies vaccine in?
What are the side effects of Imovax® Rabies: inactivated rabies vaccine?
Related
- Drug class: All Inactivated vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention of rabies
- Also known as: Imovax® Rabies
- Compare: Imovax® Rabies: inactivated rabies vaccine vs similar drugs
- Pricing: Imovax® Rabies: inactivated rabies vaccine cost, discount & access